LNTH vs SUPN
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LNTH · Lantheus$102.10 ▲ 0.00%
SUPN · Supernus Pharmaceuticals$28.61 ▲ 0.92%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LNTH +80.7%
- SUPN -36.6%
Head to head
| Metric | LNTH | SUPN |
|---|---|---|
| Price | $102.10 | $28.61 |
| Change today | ▲ 0.00% | ▲ 0.92% |
| Market cap | $6.68B | $5.94B |
| Return, 3 months | +1.3% | -36.6% |
| Return, year to date | +53.4% | -42.4% |
| Return, 1 year | +82.9% | -36.9% |
| P/E (TTM) | 25.4 | – |
| P/B | 4.9 | 5.6 |
| P/E percentile vs own 5y | 68th | 20th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +1.5% | +18.0% |
| Net profit growth (YoY) | -19.4% | +146.4% |
| Gross margin | 61.3% | 87.6% |
| Operating margin | 18.6% | 3.2% |
| Net margin | 17.3% | -5.1% |
| Return on equity | 21.8% | -4.2% |
| Analyst target vs. price | +5.0% | +83.9% |
| Analyst buy share | 0% | 83% |
| RSI (14) | 69 | 36 |
| 30-day volatility | 4.1% | 127.6% |
| Max drawdown, 1 year | -12.2% | -53.6% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LNTH is the largest of the group by market value.
- LNTH has returned the most over the past year.
- SUPN is growing revenue fastest.
- LNTH keeps the most profit per dollar of sales.
- LNTH has been the calmest stock over the last 30 days.